Skip to main content
Gufic BioSciences Ltd. logo

Gufic BioSciences Ltd. — Investor Relations & Filings

Ticker · GUFICBIO ISIN · INE742B01025 LEI · 3358003C6YDH6EIDBP63 BSE.NS Manufacturing
Open in API
Filings indexed 1,192 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country IN India
Listing BSE.NS GUFICBIO

About Gufic BioSciences Ltd.

https://gufic.com/

Gufic BioSciences Ltd. focuses on the research, development, and large-scale manufacturing of pharmaceutical formulations and active pharmaceutical ingredients. The organization is distinguished by its specialized expertise in lyophilization technology, operating extensive facilities for the production of freeze-dried injectables. Its product portfolio encompasses a wide range of therapeutic areas, including critical care, infertility, oncology, and gastroenterology. In addition to conventional medicine, the company develops proprietary herbal and ayurvedic formulations through integrated scientific research. Gufic emphasizes advanced drug delivery systems and maintains a significant presence in the production of antibiotics, antifungal agents, and cardiac medications. The company serves a global clientele by providing high-quality generic and specialty healthcare solutions.

Recent filings

Filing Released Lang Actions
Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026 is attached herewith
Regulatory Filings Classification · 90% confidence The document is a Secretarial Compliance Report prepared by the Company Secretary under SEBI Listing Regulations (LODR Reg. 24A) certifying compliance with various statutory requirements for the year ended March 31, 2026. It is an attestation/certification letter submitted to stock exchanges and does not contain substantive financial statements, strategic investor material, or direct regulatory action updates. It is therefore best classified under the fall-back category for general regulatory submissions and officer certifications.
2026-05-27 English
Intimation of Earnings Conference Call scheduled to be held on June 01, 2026 is attached herewith.
Regulatory Filings Classification · 85% confidence The document is a notice to stock exchanges under SEBI Listing Obligations announcing the scheduling of an upcoming earnings conference call. It does not present any financial results, actual report content, or Q&A transcript, nor is it a formal earnings release with key highlights. It is a regulatory announcement/invitation and thus best fits the general “Regulatory Filings” category (RNS).
2026-05-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 45% confidence The document is an exchange filing under SEBI LODR Regulation 30 notifying the stock exchanges and investors of an upcoming earnings conference call. It contains no financial results, statements, or detailed report; it is not a transcript of a call, nor an earnings release with numbers. It is essentially a regulatory disclosure/announcement. Therefore it best fits the fallback category for general regulatory announcements.
2026-05-25 English
Gufic Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Audited Financial Results ....
Board/Management Information Classification · 92% confidence The document is a formal intimation under SEBI Listing Regulations informing stock exchanges of a scheduled Board of Directors meeting to consider approving audited financial results and recommending a dividend. It is not the meeting materials or AGM materials themselves, nor is it a financial report. This type of announcement—scheduling a board meeting—is classified as Board/Management Information (MANG).
2026-05-22 English
Update on further investment in Selvax Pty Ltd. is attached herewith
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding a further investment in Selvax Pty Ltd. It references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content details the nature of the investment, the target company, the cost, shareholding percentages, and strategic rationale. There is no financial statement or comprehensive financial report included; rather, it is an update on a capital investment transaction. The document length is 8999 characters, which is substantial but the content is clearly an announcement of a financing event rather than a full financial report or earnings release. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2026-04-29 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is an official communication from Gufic Biosciences Limited to stock exchanges (BSE and NSE) regarding a further investment in Selvax Pty Ltd. It references compliance with SEBI Listing Regulations, specifically Regulation 30 related to disclosure of material events. The content details the nature of the investment, the target company, the cost, shareholding percentage, and strategic rationale. There are no financial statements or detailed financial performance data presented, nor is this a full report or earnings release. The document is an update on a capital investment transaction, specifically a further investment in an associate company. This fits the category of Capital/Financing Update (CAP) as it relates to company fundraising or capital structure changes. The document length (8857 characters) and detailed disclosure support this classification rather than a brief announcement or regulatory filing. Therefore, the filing type is CAP with high confidence.
2026-04-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.